These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7976393)

  • 21. Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
    Packham MA; Bryant NL; Guccione MA
    Thromb Haemost; 1990 Apr; 63(2):282-5. PubMed ID: 2363129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and comparison of tripeptidylfluoroalkane thrombin inhibitors.
    Neises B; Broersma RJ; Tarnus C; Piriou F; Remy JM; Lintz C; Heminger EF; Kutcher LW
    Bioorg Med Chem; 1995 Aug; 3(8):1049-61. PubMed ID: 7582979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemistry and biology of the peptide anticoagulant D-MePhe-Pro-Arg-H (GYKI-14766).
    Bajusz S
    Adv Exp Med Biol; 1993; 340():91-108. PubMed ID: 8154347
    [No Abstract]   [Full Text] [Related]  

  • 24. GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: "in vitro" and "in vivo" studies.
    Tremoli E; Colli S; Paoletti R
    Adv Exp Med Biol; 1984; 164():187-92. PubMed ID: 6695572
    [No Abstract]   [Full Text] [Related]  

  • 25. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
    Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
    Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting.
    Greenberg CS; Miraglia CC; Rickles FR; Shuman MA
    J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
    Yamamoto J; Inoue N; Otsui K; Ishii H; Gorog DA
    Thromb Res; 2014 May; 133(5):919-26. PubMed ID: 24613697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogen-substrate assay--as a tool for monitoring a new thrombin inhibitor.
    Rásky K; Pátfalusi M; Vereczkey L
    Acta Pharm Hung; 1993 Jan; 63(1):3-12. PubMed ID: 8452033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1.
    Keuren JF; Wielders SJ; Ulrichts H; Hackeng T; Heemskerk JW; Deckmyn H; Bevers EM; Lindhout T
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1499-505. PubMed ID: 15845904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
    Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
    Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin.
    Krstenansky JL; Broersma RJ; Owen TJ; Payne MH; Yates MT; Mao SJ
    Thromb Haemost; 1990 Apr; 63(2):208-14. PubMed ID: 2363122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of platelet factor 4 on inhibited thrombin substrate reactions.
    Abildgaard U; Odegård OR; Kierulf P; Pepper DS
    Thromb Res; 1974 Aug; 5(2):185-96. PubMed ID: 4472150
    [No Abstract]   [Full Text] [Related]  

  • 33. Interaction of RGD liposomes with platelets.
    Nishiya T; Sloan S
    Biochem Biophys Res Commun; 1996 Jul; 224(1):242-5. PubMed ID: 8694820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous-flow injection microfluidic thrombin assays: The effect of binding kinetics on observed enzyme inhibition.
    Ramjee MK; Patel S
    Anal Biochem; 2017 Jul; 528():38-46. PubMed ID: 28456636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative studies in vitro and ex vivo on the anticoagulant effect of a reversible and an irreversible tripeptide inhibitor of thrombin.
    Bagdy D; Barabás E; Bajusz S; Széll E; Fehér A
    Thromb Res; 1992 Jul; 67(2):221-31. PubMed ID: 1440524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an orally active tripeptide arginal thrombin inhibitor.
    Shuman RT; Gesellchen PD
    Pharm Biotechnol; 1998; 11():57-80. PubMed ID: 9760676
    [No Abstract]   [Full Text] [Related]  

  • 37. Gly-pro-arg-pro (GPRP) enhances free thrombin.
    Gallistl S; Muntean W; Zenz W
    Thromb Res; 1995 Jun; 78(6):547-50. PubMed ID: 15714756
    [No Abstract]   [Full Text] [Related]  

  • 38. Dynamic thrombosis and thrombolysis. Role of antithrombins.
    Chesebro JH; Fuster V
    Circulation; 1991 May; 83(5):1815-7. PubMed ID: 2022032
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative studies on the antithrombin potency of various thrombin inhibitors, as determined by using an amidolytic method.
    Callas DD; Fareed J
    Thromb Res; 1996 Jul; 83(1):97-102. PubMed ID: 8837308
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombin inhibition by the highly selective 'reversible suicide substrate' N-ethoxycarbonyl-D-phenylalanyl-L-prolyl-alpha-azalysine p-nitrophenyl ester.
    Ascenzi P; Gallina C; Bolognesi M
    Protein Pept Lett; 2005 Jul; 12(5):433-8. PubMed ID: 16029155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.